Annexin Pharmaceuticals AB Logo

Annexin Pharmaceuticals AB

ANNX | ST

Overview

Corporate Details

ISIN(s):
SE0009664154
LEI:
5493000JP703HGPJEX27
Country:
Sweden
Address:
KAMMAKARGATAN 48, 111 60 Stockholm
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Annexin Pharmaceuticals AB is a clinical-stage biotechnology company focused on developing therapies centered on the human protein Annexin A5. The company's lead drug candidate, ANXV, is a recombinant form of Annexin A5 designed to target the lipid phosphatidylserine (PS), which is exposed on the surface of stressed and damaged cells. By binding to PS, ANXV aims to create a protective shield that counteracts cellular stress, modulates immune responses, and repairs tissue injury. The company is primarily investigating ANXV's therapeutic potential in ophthalmology, specifically for Retinal Vein Occlusion (RVO), where it is positioned as a potential First-in-Class treatment, and in oncology. The drug's unique mechanism of action offers a novel approach for various diseases where PS exposure is a contributing factor.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Annexin Pharmaceuticals AB. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Annexin Pharmaceuticals AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Annexin Pharmaceuticals AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Purple Biotech Ltd. Logo
Develops first-in-class cancer therapies targeting tumor immune evasion and drug resistance.
Israel PPBT
Develops uncopiable atomic fingerprints for anti-counterfeiting, verifiable by smartphone.
United Kingdom N/A
QUANTUM BLOCKCHAIN TECHNOLOGIES PLC Logo
R&D firm using AI and quantum computing to create efficient technologies for Bitcoin mining.
United Kingdom QBT
Quantum Genomics Logo
Develops digital twin solutions to simulate drug effects and personalize treatments.
France ALQGC
QUIA PHARMA AB Logo
Develops enhanced drugs using a patented, releasable pegylation drug delivery platform.
Sweden QUIA
Read Gene Spolka Akcyjna Logo
Develops DNA tests to identify genetic cancer risk for early detection and prevention.
Poland RDG
RELIEF Therapeutics Holding AG Logo
Developing and commercializing novel therapies for rare and ultra-rare diseases.
Switzerland RLF
Respiratorius AB Logo
Developing innovative drug candidates to enhance standard therapies for aggressive cancers.
Sweden RESP
ROQUEFORT THERAPEUTICS PLC Logo
Developing novel immuno-oncology medicines for hard-to-treat, resistant cancers.
United Kingdom ROQ
United States of America N/A